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ABSTRACT
Objective: Total laparoscopic radical hysterectomy
(TLRH) makes it difficult to resect adequate vaginal cuff
according to tumor size and to avoid tumor spread after
opening the vagina. Laparoscopic-assisted radical vaginal
hysterectomy (LARVH) is associated with higher risk for
urologic complications.
Methods: The vaginal-assisted laparoscopic radical hys-
terectomy (VALRH) technique comprises 3 steps: (1) com-
prehensive laparoscopic staging, (2) creation of a tumor-
adapted vaginal cuff, and (3) laparoscopic transsection of
parametria. We retrospectively analyzed data of 122 pa-
tients who underwent VALRH for early stage cervical can-
cer (n110) or stage II endometrial cancer (n12) be-
tween January 2007 and December 2009 at Charite ´
University Berlin.
Results: All patients underwent VALRH without conver-
sion. Mean operating time was 300 minutes, and mean
blood loss was 123cc. On average, 36 lymph nodes were
harvested. Intra- and postoperative complication rates
were 0% and 13.1%, respectively. Resection was in sound
margins in all patients. After median follow-up of 19
months, disease-free survival and overall survival for all
110 cervical cancer patients was 94% and 98%, and for the
subgroup of patients (n90) with tumors pT1b1 N0 V0
L0/1 R0, 97% and 98%, respectively.
Conclusion: VALRH is a valid alternative to abdominal
radical hysterectomy and LARVH in patients with early-
stage cervical cancer and endometrial cancer stage II with
minimal intraoperative complications and identical onco-
logic outcomes.
Key Words: Laparoscopic radical hysterectomy, Urologic
complications, Radical hysterectomy, Cervical cancer.
INTRODUCTION
Radical hysterectomy is the therapy of choice for women
with early cervical cancer without lymph node metastases
and is recommended in endometrial cancer stage II pa-
tients.1,2 Nowadays, various techniques for radical hyster-
ectomy have been described: abdominal (ARH) with and
without nerve-sparing (eg, total mesometrial resection -
TMMR), total laparoscopic (TLRH), laparoscopic-assisted
vaginal (LARVH), and robotic (RRH) procedures. Besides
technical details, all available publications provide pro-
spective, retrospective, or match-paired data (with histor-
ical cohorts) to characterize each procedure. Except one
Phase II randomized study comprising only 15 patients,
no large prospective randomized study exists comparing
different radical hysterectomy approaches.3,4
All comparisons between open and laparoscopic-based
radical operations for the treatment of women with early
cervical cancer favor laparoscopy with respect to blood
loss, hospital stay, recovery, cosmetic result, and identical
oncologic outcome, if reported.1,5-25 LARVH has been suc-
cessfully performed in more than 800 patients with ac-
ceptable oncologic outcomes but has been associated
with a higher rate of intra- and postoperative urologic
complications compared to ARH and TLRH.1,6,14,15,22
Moreover, the vaginal part of LARVH is difficult to teach.
Despite the use of uterine manipulators in TLRH, estima-
tion of adequate vaginal resection is often difficult. Addi-
tionally, this manipulation potentially leads to tumor spill-
age, especially when the vagina is opened and the tumor
surface is exposed to circulating CO2.16,19,20,24,25 First stud-
ies on RRH seem to overcome the limitations of conven-
tional laparoscopy, such as 2-dimensional visualization,
limited degree of instrument motion, and surgeons dis-
comfort and, thus, lead to better acceptance of minimally
invasive techniques in gynecologic oncology.7,11,26-28
However, no vaginal access is possible, and problems
with vaginal cuff creation are similar to those of TLRH.
Moreover, use of the robotic system is associated with
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SCIENTIFIC PAPERhigh costs. Up to now, very few oncologic results are
available29; therefore, RRH is still under evaluation.
In Landoni’s 1997randomized study,30 oncologic equality of
radical hysterectomy and primary radiation for the treatment
of patients with early cervical cancer was demonstrated.
Since 1999, no new study has been conducted comparing
chemoradiation and surgery. Careful and individual selection
of patients to one of these treatment modalities is essential to
avoid increased toxicity using both therapies. Only operative
staging, best done by laparoscopy, can provide exact staging
of disease and can help to identify patients who profit mostly
from radical hysterectomy.31
According to LeBlanc’s hint,32 we modified LARVH into
VALRH (vaginal-assisted laparoscopic radical hysterec-
tomy), which ideally combines advantages of vaginal and
laparoscopic approaches after comprehensive staging.
The present article describes the technique of VALRH
together with operative and early oncologic results.
METHODS
Patient Characteristics
After obtaining Institutional Review Board approval, the
prospectively maintained Gynecologic Service Database
was used to identify all 122 patients who underwent
VALRH between January 2007 and December 2009 at the
Department of Gynecology at Charite ´ University Berlin,
Campi Benjamin Franklin and Mitte. Indications for VALRH
were histologically proven cervical cancer (n110) and en-
dometroid endometrial cancer (n12) after curettage.
One patient requested to undergo radical hysterectomy
type B in case of extensive CIN III lesion not completely
resected by conization (Table 1).
The following parameters were analyzed: age, BMI, op-
erating time, blood loss, node counts, and length of hos-
pital stay, as well as time to spontaneous voiding of urine,
intra- and postoperative complications.
Surgical Technique
Preoperatively, each patient underwent bowel prepara-
tion. Surgery was always performed with the patient re-
ceiving perioperative antibiotics (1.5g cefuroxime and
500mg metronidazole), general endotracheal anesthesia,
and thrombosis prophylaxis. All patients consented to
undergo radical hysterectomy using this new technique.
The VALRH consists of 3 parts: (1) laparoscopic staging
including lymphadenectomy, to evaluate nodal status, and
dissection of vesicocervical and vesicovaginal septum to
evaluate tumor relation to adjacent organs, (2) vaginal
creation of a tumor-adapted cuff, and (3) laparoscopic
radical hysterectomy.
For laparoscopic staging, the patient is placed in a deep
Trendelenburg position (30°) with straight legs. After
pneumoperitoneum is obtained, 5 trocars are placed: a
10-mm trocar through the umbilicus, an additional 10-mm
trocar in the left medioclavicular line 2 fingers above the
umbilicus, and three 5-mm trocars in the lower abdomen
2cm to 3cm below the umbilicus level bilaterally to the
epigastric arteries and in the midline suprapubically. The
intraabdominal pressure is maintained at 15mm Hg. After
careful inspection of the abdominopelvic cavity to rule out
intraabdominal spread, cytology is taken from the cul de
sac. If present, adhesions are taken down.
Depending on tumor entity and FIGO stage, pelvic 
paraaortic lymphadenectomy is performed as previously
described.31 In patients with proven cervical cancer, all
removed lymph nodes are sent for frozen section. Dissec-
tion of the bladder up to the level of the ventral vaginal
wall is done while waiting for frozen section results. In
case of lymph node metastasis, the procedure is aban-
doned, and patients are referred for primary chemoradia-
tion. Only if frozen section reveals tumor-free lymph
nodes is the patient placed in a lithotomy position with
extended legs for the vaginal part.
The aim of the vaginal part is to create a tumor-adapted
cuff and to open vesicovaginal and rectovaginal spaces.
According to tumor size, adequate length of the vagina is
grasped with 6 straight clamps (Figure 1 A). A diluted
solution of epinephrine-Xylocaine is injected under the
vaginal mucosa for vasoconstriction followed by mono-
polar incision distally to the clamps. Vaginal cuff is now
Table 1.
Patient Characteristics
Number of women 122
Age 47 (27–82)
BMI (kg/m
2) 24.9 (17.3–46.3)
Parity 2 (0–6)
Histology (%)
Adenocarcinoma cervix 40 (32.8)
Squamous cell carcinoma cervix 67 (54.9)
Neuro-endocrine cervical carcinoma 2 (1.7)
CIN III 1 (0.8)
Endometrial cancer (diagnosed by D&C) 12 (9.8)
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fore the tumor is always covered to prevent spillage of
cancer cells. With 6 serrated clamps, tension is brought on
the closed vaginal cuff to open the vesicocervical and
rectovaginal space as well as the cul-de-sac. The inferior
part of the rectovaginal ligament is now transected bilat-
erally and the uterus can be pushed intra-abdominally
after removal of the serrated clamps (Figure 1 C). The
vaginal cuff is continuously sutured for hemostasis. Addi-
tionally, interrupted sutures are placed for later closure of
the vagina (Figure 1 D). To preserve pneumoperito-
neum, a wet surgical towel is placed into the vagina.
For the third part of VALRH, the patient is placed again
into the Trendelenburg position with straight, slightly ab-
ducted legs. Now the parametrium is resected. As a result
of the vaginal route, both bladder pillars and the starting
point and end point of parametrial resection are easy to
identify (Figures 2A and B). The operation starts by
coagulation and transsection of the uterine vessels at their
origin from iliac internal vessels (Figure 2C). In case of
salpingo-oophorectomy, infundibulopelvic ligaments are
coagulated and cut. By pulling the vascular part of the
cardinal ligament medially, the ureter is freed out of its
tunnel up to the bladder entry. Now, the remaining part of
the paracervix is identified, coagulated and transected
under permanent visualization of the ureter. Plexus pel-
vicus and splanchnic and hypogastric nerves are sepa-
rated and preserved (Figure 3A and B). The suture of the
closed vaginal cuff is easily identified and marks the end-
point of resection. The specimen is removed transvagi-
nally, and the vagina is now closed using the preplaced
interrupted sutures (Figure 4). Finally hemostasis is veri-
fied, and a suprapubic catheter and 2 drains are placed. The
surgeon intraoperatively chooses, the radicality of parame-
trial resection in correlation to tumor size according type II
(B) or III (C) radical hysterectomy. In 25 patients, parametrial
resection was done with the da Vinci robotic system, in the
others it was done by laparoscopy. No uterine manipulator
Figure 1. A. Creation of tumor-adapted vaginal cuff; B. Closure of the vaginal cuff with a continuous suture; C. Transsection of distal
rectovaginal ligament after opening of cul-de-sac; D. Vaginal margin covered by a continuous suture. Six sutures are placed for later
closure of the vagina. Uterus with closed vaginal cuff is pushed intraabdominally.
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consultants in our unit. One of them would perform the
operation with the assistance of one gynecologic fellow or
resident, who took over sections of the operation, ie, oppo-
site side of lymphadenectomy.
Postoperative Course
We left the suprapubic catheter in place until the patient
was able to empty her bladder spontaneously with resid-
ual volume 50cc. All women received weight adapted
low-molecular-weight heparin and a low-fat diet to re-
duce lipid concentration in the lymphatic fluid. Drains
were removed if fluid was 100cc.
Statistical Analysis
Patient’s data, surgical outcome, and histologic results
were extracted from medical charts. The postoperative
follow-up was measured from the date of operation to the
date of the last follow-up visit or death. Statistical analysis
was performed using SPSS software (version 16.0). Over-
all survival (OS) and disease-free survival (DSF) were
calculated according to Kaplan-Meier.
RESULTS
Operative Data
All 122 patients underwent VALRH without conversion to
laparotomy. Type II (B) and type III (C) operations were
performed in 82 and 40 patients, respectively. VALRH was
combined with pelvic lymphadenectomy in 37, and with
pelvic and paraaortic in 85 patients. Mean operating time
was 300 minutes. Operation time was nearly identical for
type B and C procedures. Duration of surgery differed
significantly in 2 patients, one with infiltrative sigmoid
endometriosis, who had to undergo simultaneously bowel
resection (operating time 665 minutes) and one patient
with a BMI of 46 (605 minutes). Learning curve increased
over time, which can be seen in the operating times.
From 2007 to 2008, operating time decreased for VALRH
Type II and III from 317 to 278 minutes and from 345 to 312
minutes, respectively. Between 2008 and 2009, operation
times changed for Type II and III operations from 278 to 275
and 312 to 303. In all, operation times between 2007 and
2009 could be phased down 42 minutes for both types.
Figure 2. A. Intraoperative situs after vaginal part. Both bladder pillars (arrows) are under tension. Vesicocervical and vesicovaginal
septum are complete dissected; B. Magnified view between bladder pillars to transsected vagina (arrow) and closed vaginal cuff (star);
C. Transsection of uterine vessels and bladder pillar. The transsection area in a type II (B).
Figure 3. A. Adaption of parametrial resection type II (contin-
uous line) and type III (interrupted line); B. Intraoperative situs
of parametrial resection type II (continuous line) and type III
(interrupted line).
Figure 4. Postoperative specimen after type II procedure. Vag-
inal cuff is marked with continuous arrow, parametria with
interrupted arrows.
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(range, 4 to 83) with 21 (range, 4 to 43) pelvic and 15
(range, 2 to 36) paraaortic lymph nodes. Additionally, 36
patients underwent the sentinel node harvesting prior to
completion of the lymphadenectomy. One patient (cervi-
cal cancer pT1a2 N0 L0 V0 R0) refused complete pelvic
lymph node dissection, and therefore only 4 sentinel
lymph nodes were removed, which were tumor free on
histology (Table 2).
Not a single intraoperative complication occurred, in par-
ticular, no bladder or ureter injury. Mean blood loss was
123cc (range, 10 to 400). One patient required blood
transfusion due to stress-induced cardiomyopathy and 2
patients due to preoperative anemia on the demand of the
anesthesiologist. Postoperative complication rate was
13.1% (Table 3). No patient required postoperative refer-
ral to a urogynecologist for postoperative bladder dys-
function, and only one patient needed 25 days to void
her bladder adequately. Mean time to urine residuals
50cc was 7.9 days. Four patients had to undergo relapa-
roscopy; 1 due to lost drainage, 2 for suspected ileus
(which could not be verified intraoperatively), and 1 for
chyloperitoneum. Between 10 days and 40 days postop-
erative, 3 patients developed a ureterovaginal fistula,
which was treated with ureteral stents without complica-
tion. Two of these patients underwent VALRH performed
with the da Vinci robotic surgical system.
Histologic Results
Parametrial and vaginal resection was in sound margins in
all patients. Preoperatively, the extent of endometrial can-
cer to the cervical stroma was diagnosed through dilation
and curettage in 12 patients but was confirmed postoper-
atively in only 2 patients. Cervical cancer was diagnosed
preoperatively by biopsy or conization in 109 patients.
One patient with extensive CIN III and R1 conization
insisted on radical hysterectomy to get the highest possi-
ble oncologic safety. The majority of patients were found
to have FIGO stage IB1 (75.5%). In 6 patients (5.5%), final
pathology revealed parametrial involvement. Histological
types were distributed as follows: squamous cell carci-
noma 60.9%, adenocarcinoma 36.4%, and neuro-endo-
crine carcinoma 1.8% (Table 4). Two patients underwent
VALRH after neoadjuvant chemotherapy. In the final his-
topathological examination, 5/110 (4.5%) patients with
cervical cancer had positive micrometastases/metastases
undetected by frozen section. In 4/110 (3.6%) hysterec-
tomy specimens, the preoperative diagnosis of negative
lymphovascular space involvement (L0) had to be cor-
rected postoperatively to L1.
Adjuvant Therapy
Postoperative adjuvant therapy (radiation, chemotherapy,
radiochemotherapy) was recommended for 30/122 pa-
tients (24.6%), 8 with endometrial cancer, and 22 with
cervical cancer. Six patients with endometrial cancer stage
IA G2 underwent vaginal brachytherapy. One patient
with endometrial cancer and a synchronous 4-cm Sertoli
ovarian tumor (stage IA) received pelvic radiation. Pelvic
Table 2.
Operative Data
VALRH n122
VALRH type II (B) n82
VALRH type III (C) n40
Operation time (minutes) 300 (175–655)
Blood loss (mL) 123 (10–400)
Median nodal yield (nodes) 36 (4–83)
Pelvic 21 (4–43)
Paraaortic 15 (2–36)
Median time to urine residuals 50mL (days) 7.9 (2–40)
Median hospital stay (range) 10.4 (4- 31)
Table 3.
Complication Rates
Number of patients n122
Blood transfusions 3 (not surgical related)
Intraoperative complications 0
Postoperative complications 16 (13.1%)
4 re-laparoscopies
- 2x for suspected ileus
- 1x for lost drainage
- 1x for cholascos
2 pulmonary emboli in CT scan
(without clinical evidence)
3 ureterovaginal fistula
1 vaginal suture dehiscence
1 cardiomyopathy
1 symptomatic lymphocele
4 fever
- 2x unknown reason
- 1x colitis ulcerosa
- 1x UTI (E. coli)
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tion indicated chemoradiation in one young woman with
endometrial cancer.
Recommendation for adjuvant chemoradiation or chemo-
therapy was given for cervical cancer patients and proved
high risk factors (N1, M1, stage IIB) or the combination of
2 intermediate risk factors (tumor size 4cm, LVSI, ade-
nocarcinoma, G3, deep stromal invasion). In 2 of 22 pa-
tients, a neuro-endocrine tumor was found that was
treated according to a multimodal protocol. In 6 and 4
patients, final histologic result revealed stage IIB or lymph
node positivity and, therefore, need for adjuvant chemo-
radiation. Other reasons for chemoradiation were the
combination of L1 and V1 in 3 patients, stage IIA and G3
in one patient, G3 and L1 in one patient, and L1 adeno-
carcinoma in another young patient.
Only one patient (0.9%) underwent vaginal brachytherapy
based on surgical result (close margin of 5-mm vaginal).
Individual procedures were performed in 2 patients: 1
patient with cervical cancer stage IB2 was treated by
neoadjuvant chemotherapy and underwent postoperative
chemoradiation, and another patient received brachyther-
apy only due to grading of 3. In one patient with ovarian
metastasis, 6 cycles of platen-based chemotherapy were
administered. Two patients denied recommended chemo-
radiation.
Follow-up
After a mean follow-up of 19 months (range, 4 to 40), the
total recurrence rate in the entire cohort was 6.7% (8/120),
for cervical cancer patients 6.4% (7/110), and for endo-
metrial cancer 8.3% (1/12), respectively. DFS and OS for
Table 4.
Postoperative Histological Results After VALRH
Cervical Cancer n110 No (%) Endometrial Cancer n12 No (%)
Postoperative stage Postoperative stage (new FIGO system)
CIN III 1 (0.9) 1A
IA1 L1 10 (9.1) 1B 9 (75)
IA2 5 (4.5) 2B 1 (8.3)
1B1 83 (75.5) 2 (16.7)
ypT1B1 2 (1.8)
1B2 2 (1.8)
IIA 1 (0.9)
IIB 6 (5.5)
Grading Grading
1 14 (12.7) 1 4 (33,3)
2 61 (55.5) 2 8 (66,7)
3 27 (24.5) 3 0 (0)
unknown 8 (7.3)
Histologic type
CIN III 1 (0.9)
Adenocarcinoma 40 (36.4)
Squamous cell carcinoma 67 (60.9)
Neuro-endocrine carcinoma 2 (1.8)
Lymphangiosis (L) Lymphangiosis
no 85 (77.3) no 11 (91.7)
yes 25 (22.7) yes 1 (8.3)
Hemangiosis (V) Hemangiosis
no 103(93.6) no 12 (100)
yes 7 (6.4) yes 0 (0)
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the subgroup of patients (n90) with tumors pT1b1 N0
V0 L0/1 R0, 96.7% and 97.8%, respectively.
DISCUSSION
Radical hysterectomy is the operative standard procedure in
patients with early cervical cancer, and the recommended op-
eration in stage II endometrial cancer. Today, a broad spectrum
of open,33-35 total laparoscopic,5,7-12,16,18-20,24-26 laparoscopic-
assisted vaginal,1,4,6,13-15,17,22 and robotic7,11,21,26-29 tech-
niques are described. Operative data of these different
techniques are summarized in Table 5. Recently pub-
lished studies comprise 7 to 400, 8 to 200, 8 to 317, and 7
to 80 patients for ARH, LARVH, TLRH, and RRH, respec-
tively (for literature see Table 5).
There are 3 main criteria to use to evaluate and compare
different techniques of radical hysterectomy: (1) possibil-
ity to triage patients and therefore avoid combined use of
operation and chemoradiation, (2) complication rate, and
(3) oncologic outcome. Our intent was to modify previ-
ously used LARVH into VALRH to reduce a high urologic
complication rate with similar oncologic results.
Operative staging including pelvic  paraaortic lymph-
adenectomy is the key step to differentiate patients who
benefit from radical surgery from those who are better
treated by primary chemoradiation.30 TLRH, RRH, LARVH,
and VALRH offer the possibility to start with lymph node
dissection ( sentinel node) and frozen section. How-
ever, frozen section was not routinely used in all centers.
We strictly have abandoned radical hysterectomy in cases
of positive lymph nodes. However, frozen section was not
accurate in 4 of 110 (3.6%) patients with cervical cancer in
our series. Bader et al36 reported a false-negative rate for
frozen sections of 17%.
Most published retro- or prospective studies on radical
hysterectomy include cervical cancer patients with stages
IA1 L1 – IIA (B) and only a few higher stages (Table 5).
This was in concordance with our study population. Con-
version rates are described as up to 5%, 10%, and 14% for
RRH, TLRH, and LARVH, respectively. None of our
planned VALRH-procedures had to be converted to the
open approach. ARH, LARVH, and our new technique of
VALRH are done without any manipulator to create an
adequate vaginal cuff, whereas nearly all TLRH and RRH
require a manipulator or sponge in the vagina. Creation of
a vaginal cuff by the transvaginal approach seems to be
easier and avoids any tumor distribution due to manipu-
lator use. With the described technique of VALRH, we
were able to resect tumor always in sound vaginal margins
in contrast to some studies of ARH, TLRH, and RRH where
up to 20% of positive vaginal margins are reported had to
be considered (Table 5).
Blood loss in our study was low compared to that in ARH
and LARVH and in the lower range of TLRH and RRH.
Therefore, transfusion was given to only 3 patients, where
it had not been caused by intraoperative blood loss. Op-
eration time of 300 minutes in our cohort is longer than
the average time for ARH, TLRH, and RRH (Table 5).
However, one must consider that 85 of 122 (69%) of our
patients also underwent paraaortic lymph node dissection
with a duration of approximately 60 minutes. The majority
of radical hysterectomies reported in the literature are
combined with pelvic lymph node dissection exclusively.
Subsequently, the mean number of harvested lymph
nodes (n36) in our cohort is in the upper range of all
described studies and often higher than in open surgery
(Table 5).
Table 5.
Literature Review and Comparison of Different Techniques of
Radical Hysterectomy
TLRH ARH Technique
IA1 L1-IIIB
12,25 IA1 L1-III
15,33 Stages
55–400
18 221–2000
21,28 Blood loss (cc)
1–23
23,24 8 [gt] 50i
20,33 Transfusion (%)
0–17.7
7,25 1.4–21.4
7,35 Non in sano (R1)-
resection (%)
92–371
10,25 95–391
35 OR-time (minutes)
0–11.8
7,18 4–12.5
4,2 Intra-operative
complications (%)
10–34
16 12–46
6,35 Lymph node number
5.1–40
5,9 4.7–40
29 Postoperative
complications (%)
0–10.5
24 — Conversion rate (%)
VALRH Own Data RRH LARVH
IA1 L1-IIA IA1-IIB
28,29 IA1-IVA
0
123 50–300
28,29 272–666
13,22
0.2 Surgical-
related (0%)
0–7.5
21 7 [gt] 50
14,15
0 0–15.6
7,27 n.i.
300 129–434
28,29 180–333
1,4
0 0–14
26 5.9–13.2
6
36 13–32
7,26 15–33
15
13.1 3%-59%
27,29 8%-22.6
1
0 0–5
21,27 0–14%
4,22
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12.5%, 0% to 11.8%, 5.9% to 13.2%, and 0% to 14% in ARH,
TLRH, LARVH, and RRH, respectively. Interestingly, there
was not one intraoperative complication in our study.
Also, the postoperative complication rate in our study
(13.1%) is in the lower range of published data (Table 5).
In particular, urologic intra- and postoperative complica-
tions are significantly lower compared to those in LARVH1
or TLRH. Because 2 of 3 ureterovaginal fistulae in our
series are associated with the use of the da Vinci, we
believe that this reflects the fact that we did not pass the
learning curve completely with our robotic skills. A fre-
quent reported postoperative complication of RRH, vagi-
nal dehiscence, which is described in 3.1% to 21%,7,21,27
occurred partially in only 1 of our patients (0.8%) and was
treated conservatively.
Adjuvant therapy was recommended to 24.6% of all our
patients. After exclusion of 8 patients with endometrial
cancer, 2 patients with neuroendocrine cervical tumors
(multimodal therapy), and 4 undetected lymph node me-
tastases, the rate of adjuvant therapy decreased to 12.7%.
This percentage is in our opinion an acceptable range
with the philosophy of avoiding combined treatment of
radical hysterectomy and chemoradiation, compared with
other studies where adjuvant therapy was performed in
30% up to 63% of patients.4,6,7,29
Oncologic data are difficult to compare, because of dif-
ferent follow-up intervals and various oncologic corner-
stones. Summarizing data from open, laparoscopic, lapa-
roscopic-vaginal, and robotic series, recurrence rates vary
between of 0% and 13%, DFS between 82% and 100%, and
OS between 89% and 100%. Despite a relatively short
follow-up of 19 months, our DFS rate of 94% and OS rate
of 98% is promising. However, longer follow-up is man-
datory to confirm these data.
CONCLUSION
Our new technique of VALRH is an oncologically valid al-
ternative to ARH, LARVH, TLRH, and RRH in patients with
cervical cancer IB2 and endometrial cancer stage II with
low blood loss and a minimal intraoperative complication
rate. During the vaginal part of the operation, it is always
possible to create an adequate vaginal cuff and therefore to
avoid tumor spillage and disregard the use of any manipu-
lators. Further studies comparing this new technique with
other types of radical hysterectomies are necessary to under-
line the promising results of our single-institutional series.
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